Emerging in the landscape of obesity therapy, retatrutide presents a distinct strategy. Beyond many available medications, retatrutide operates as a dual agonist, at once targeting both GLP-like peptide-1 (GLP-1) and https://jasonbitz678602.activablog.com/37752072/this-novel-retatrutide-a-glp-gip-binding-site-agonist